Incidence of metastasis to the ovaries from nongenital tract primary tumors
RG Moore, M Chung, CO Granai, W Gajewski… - Gynecologic …, 2004 - Elsevier
Objective. The purpose of this study was to evaluate the characteristics of metastatic tumors
to the ovaries in nongenital tract primaries and to determine the route of dissemination …
to the ovaries in nongenital tract primaries and to determine the route of dissemination …
A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high …
KH Lu, S Skates, MA Hernandez, D Bedi, T Bevers… - Cancer, 2013 - Wiley Online Library
BACKGROUND A 2‐stage ovarian cancer screening strategy was evaluated that
incorporates change of carbohydrate antigen 125 (CA125) levels over time and age to …
incorporates change of carbohydrate antigen 125 (CA125) levels over time and age to …
Tumor angiogenesis as a prognostic factor in cervical carcinoma
DL Wiggins, CO Granai, MM Steinhoff, P Calabresi - Gynecologic oncology, 1995 - Elsevier
Angiogenesis, the induction of new capillaries and venules, has been associated with tumor
growth. Increased tumor size and new vessel growth may further the opportunity for tumor …
growth. Increased tumor size and new vessel growth may further the opportunity for tumor …
Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation
OBJECTIVE.: Epithelial ovarian cancer has the highest mortality rate among gynecologic
cancers. Chemotherapy is an essential component of its treatment. While isothiocyanates …
cancers. Chemotherapy is an essential component of its treatment. While isothiocyanates …
Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient
DS Dizon, T Tejada-Berges, S Koelliker… - Gynecologic and …, 2006 - karger.com
Ovarian cancer is the most fatal gynecologic malignancy. Women often present late and
though median survival has improved, a majority of women will succumb to their disease …
though median survival has improved, a majority of women will succumb to their disease …
The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients
L Brard, S Weitzen, SL Strubel-Lagan, N Swamy… - Gynecologic …, 2006 - Elsevier
OBJECTIVES.: Total parenteral nutrition (TPN) for terminal ovarian cancer patients remains
controversial. In this study, we compared survival from time of terminal intestinal obstruction …
controversial. In this study, we compared survival from time of terminal intestinal obstruction …
Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma
L Brard, CO Granai, N Swamy - Gynecologic oncology, 2006 - Elsevier
OBJECTIVES.: Ovarian cancer remains a leading cause of death in women and
development of new therapies is essential. Deprivation of iron (Fe), an essential micro …
development of new therapies is essential. Deprivation of iron (Fe), an essential micro …
Vulvar epithelioid sarcoma in pregnancy
RG Moore, MM Steinhoff, CO Granai, LR DeMars - Gynecologic oncology, 2002 - Elsevier
Background. Epithelioid sarcoma is a soft tissue tumor rarely found centrally and even less
commonly on the vulva. Vulvar sarcoma in pregnancy is also exceedingly rare with only five …
commonly on the vulva. Vulvar sarcoma in pregnancy is also exceedingly rare with only five …
Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf
S Kalkunte, L Brard, CO Granai, N Swamy - Angiogenesis, 2006 - Springer
Angiogenesis is a complex process involving coordinated steps of endothelial cell
activation, proliferation, migration, tube formation and capillary sprouting with participation of …
activation, proliferation, migration, tube formation and capillary sprouting with participation of …
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program
DS Dizon, J Schwartz, A Rojan, J Miller, L Pires… - Gynecologic …, 2006 - Elsevier
PURPOSE.: With the use of steroid premedication, the incidence of severe hypersensitivity
reactions (S-HSR) to paclitaxel is estimated to be 2%. For those who develop a S-HSR to …
reactions (S-HSR) to paclitaxel is estimated to be 2%. For those who develop a S-HSR to …